EFFICACY OF IXEKIZUMAB IMPROVING SF-36 SCORES IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)

被引：0
|
作者：
Strand, V. [1 ]
Gottlieb, A. B. [2 ]
Kvien, T. K. [3 ]
Naegeli, A. [4 ]
Lin, C-Y. [4 ]
Benichou, O. [4 ]
Birt, J. [4 ]
机构：
[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Diakonhjemmet Hosp, Oslo, Norway
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2331
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0793
引用
收藏
页码：1334 / 1335
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 52 IN BIOLOGIC NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (SPIRIT-P1)
    Lespessailles, Eric
    Kirkham, Bruce
    Nebro, Antonio Fernandez
    Blanco, Ricardo
    Strehblow, Christoph
    Inciarte-Mundo, Jose
    Porsdal, Vibeke
    Garcia, Miriam
    Kurzawa, Monika
    Sapin, Christophe
    Geusens, Piet
    Goupille, Philippe
    Tahir, Hasan
    RHEUMATOLOGY, 2018, 57
  • [2] Efficacy and safety of ixekizumab at week 52 in biologic-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Lespessailles, E.
    Kirkham, B.
    Nebro, A.
    Alonso, R.
    Strehblow, C.
    Inciarte, J.
    Porsdal, V.
    Garcia, M.
    Kurzawa, M.
    Sapin, C.
    Geusens, P.
    Goupille, P.
    Tahir, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 44 - 45
  • [3] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 23 - 24
  • [4] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 845
  • [5] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [6] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, V.
    Fleischmann, R.
    Lespessailles, E.
    Helliwell, P. S.
    Benichou, O.
    Erickson, J.
    Shuler, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 385 - 385
  • [7] 52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Okada, Masan
    Kishimoto, Mitsumasa
    Shuler, Catherine
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 925
  • [8] Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
    Chandran, Vinod
    van der Heijde, Desiree
    Fleischmann, Roy M.
    Lespessailles, Eric
    Helliwell, Philip S.
    Kameda, Hideto
    Burgos-Vargas, Ruben
    Erickson, Janelle S.
    Rathmann, Suchitrita S.
    Sprabery, Aubrey Trevelin
    Birt, Julie A.
    Shuler, Catherine L.
    Gallo, Gaia
    RHEUMATOLOGY, 2020, 59 (10) : 2774 - 2784
  • [9] Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C.
    Mou, J.
    Moriarty, S. R.
    Lee, C.
    Gladman, D.
    Satler, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [10] Fifty two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis
    Mease, P.
    Okada, M.
    Kishimoto, M.
    Shuler, C.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S.
    Lee, C.
    Gladman, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 33
12345